Latest Market Research Reports

  GLP-1 Receptor Agonist Market Summary The global  GLP-1 receptor agonist market  size was estimated at USD 53.46 billion in 2024 and is projected to reach USD 156.71 billion by 2030, growing at a CAGR of 17.46% from 2025 to 2030. This strong growth trajectory is primarily driven by the introduction of new glucagon-like peptide 1 (GLP-1) receptor agonist products, a robust product pipeline targeting both diabetes and obesity applications, and the high clinical efficacy of these drugs in managing blood glucose levels and associated cardiometabolic conditions. Increasing awareness of obesity-related complications and type 2 diabetes is further driving the adoption of GLP-1 receptor agonists globally. In May 2024, Innovent Biologics announced that its type 2 diabetes candidate, mazdutide, outperformed Eli Lilly’s Trulicity (dulaglutide) in a Phase III clinical trial. The study demonstrated that mazdutide provided superior glycemic control and offered multiple cardiometaboli...

  GLP-1 Receptor Agonist Industry The global  GLP-1 receptor agonist market  size is expected to reach USD 156.71 billion by 2030, expanding at a CAGR of 17.46% from 2025 to 2030, according to a new report by Grand View Research, Inc. The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period. Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company ...